Market Cap 1.84B
Revenue (ttm) 0.00
Net Income (ttm) -287.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 4,103,600
Avg Vol 4,012,588
Day's Range N/A - N/A
Shares Out 134.95M
Stochastic %K 44%
Beta 2.47
Analysts Strong Sell
Price Target $21.84

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 44 716 6766461
Address:
33 Broadwick Street, London, United Kingdom
wizkid1774
wizkid1774 Jul. 4 at 11:58 PM
$CMPS I think in the next couple of weeks we are going to see some good things.
0 · Reply
Millionaire11
Millionaire11 Jul. 3 at 5:49 PM
$CMPS remember 2020 when this hyped all the way up to $60. Everything they were hyped about is happening NOW. Buckle up!
2 · Reply
QuietlyAccumulating
QuietlyAccumulating Jul. 3 at 12:02 AM
$CMPS https://thesporereport.com/psilocybin-could-help-repair-the-physical-nerve-damage-caused-by-chemotherapy/
1 · Reply
Waldo_5150
Waldo_5150 Jul. 2 at 11:29 PM
$CMPS ... "When a company files a New Drug Application (NDA) for a second indication, they don't start from scratch. COMPASS can directly copy and paste massive sections of their TRD filing into their PTSD filing" .........
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 10:12 PM
One of the strongest sectors outside of AI right now is Biotech. Neurology $DFTX Definium Therapeutics $CMPS COMPASS Pathways $DNLI Denali Therapeutics $XENE Xenon Pharmaceuticals $NBIX Neurocrine Biosciences The 70% correction trap is driving smart money into neuro-therapeutic CNS alpha pipelines. Elite institutions deploy tactical limit entries atop long-term FIB floors, lock-floating neurological monopolies. Disrupter DFTX accelerates right-side PEG defense, surging on its upsized $805M public offering and pivotal Phase 3 depression data catalysts. It pairs with psychedelic pioneer CMPS at key FIB accumulation zones, while blood-brain-barrier innovator DNLI scales following fresh Russell growth index flows. Flanking them are commercial powerhouse BIIB and pipeline leader XENE hardening their valuation ceilings. Technical compression means nothing without clinical milestones. Facing this neuro-rotation, are you buying the FIB support floors on DFTX and CMPS or resting in defensive cash?
1 · Reply
Millionaire11
Millionaire11 Jul. 2 at 10:07 PM
$CMPS 10 billion dollar market cap in the making. Millionaires in the making.
1 · Reply
twiggs462
twiggs462 Jul. 2 at 9:03 PM
$DFTX $CMPS from a couple days ago, but nice to see the coverage https://youtu.be/srT4HUojtFU?t=277&is=5X6xYSBewrec4r2s
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jul. 2 at 8:24 PM
$CMPS and $ATAI hit simultaneously in 2 minute intervals from 1:43 to 1:47 with violent, price-insensitive market order sweeps. They represented the cleanest profiles for a fund looking to deploy massive blocks into late-stage TRD pipelines. Interesting tells lay in the divergences. DFTX lagged the initial move significantly. Why? They recently closed an upsized $805M offering. That massive capital injection means float mechanics are structurally clogged with overhead supply. The market had to chew through those shares before moving up in sympathy. Meanwhile, HELP completely decoupled from the sector and flatlined. This is the risk-management filter in action. With an escalating cash burn and recent $50M underwritten dilutive offering, buy programs bypassed them. Smart money doesn’t blindly chase. They swept liquid leaders ($CMPS / $ATAI), slowly absorbed the high-supply player (DFTX)and deliberately avoided (HELP). This was simply institutional capital seeking de-risked milestones.
3 · Reply
martybecker123
martybecker123 Jul. 2 at 8:07 PM
$CMPS I guess it bounced off the bottom of the channel (or close enough). Back up we go, until 15-something at least. But hopefully we'll break out at some point.
0 · Reply
1TimeDealer
1TimeDealer Jul. 2 at 8:03 PM
$CMPS great way to head into the 250th Celebration! Whats everyones best guesses on what the stock price will be before new data??
0 · Reply
Latest News on CMPS
3 Companies Redefining Healthcare Innovation

Jun 24, 2026, 7:41 AM EDT - 10 days ago

3 Companies Redefining Healthcare Innovation

CRSP VRTX


Why Trump Is Pushing Psychedelics To Treat Mental Illness

Jun 1, 2026, 10:00 AM EDT - 4 weeks ago

Why Trump Is Pushing Psychedelics To Treat Mental Illness


Compass Pathways price target raised to $20 from $12 at Maxim

2026-05-15T15:28:25.000Z - 7 weeks ago

Compass Pathways price target raised to $20 from $12 at Maxim


COMPASS Pathways Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 7 weeks ago

COMPASS Pathways Earnings Call Transcript: Q1 2026


COMPASS Pathways Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 7 weeks ago

COMPASS Pathways Quarterly report: Q1 2026


COMPASS Pathways Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 7 weeks ago

COMPASS Pathways Earnings release: Q1 2026


COMPASS Pathways Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 7 weeks ago

COMPASS Pathways Earnings release: Q1 2026


Compass Pathways reports Q1 EPS (30c), consensus (31c)

2026-05-13T11:23:45.000Z - 7 weeks ago

Compass Pathways reports Q1 EPS (30c), consensus (31c)


COMPASS Pathways Slides: Investor presentation

May 13, 2026, 7:00 AM EDT - 7 weeks ago

COMPASS Pathways Slides: Investor presentation


Compass Pathways initiated with a Buy at Jefferies

2026-05-03T23:55:09.000Z - 2 months ago

Compass Pathways initiated with a Buy at Jefferies

JNJ


COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum

Apr 27, 2026, 11:00 AM EDT - 2 months ago

COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum


Compass Pathways initiated with a Buy at B. Riley

2026-04-24T12:57:10.000Z - 2 months ago

Compass Pathways initiated with a Buy at B. Riley


Compass Pathways enters collaboration with Osmind

2026-04-21T10:54:16.000Z - 2 months ago

Compass Pathways enters collaboration with Osmind


Psychedelic stocks rally with Trump's support

Apr 20, 2026, 8:26 AM EDT - 2 months ago

Psychedelic stocks rally with Trump's support

ATAI DFTX GHRS


COMPASS Pathways Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Proxy statement: Proxy filing


COMPASS Pathways Annual report: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 3 months ago

COMPASS Pathways Annual report: Q4 2025


COMPASS Pathways Earnings release: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 3 months ago

COMPASS Pathways Earnings release: Q4 2025


COMPASS Pathways Annual report: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 3 months ago

COMPASS Pathways Annual report: Q4 2025


COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 10:30 AM EDT - 3 months ago

COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum


COMPASS Pathways Transcript: Study update

Feb 17, 2026, 8:00 AM EST - 4 months ago

COMPASS Pathways Transcript: Study update


COMPASS Pathways Press release: Study update

Feb 17, 2026, 8:00 AM EST - 4 months ago

COMPASS Pathways Press release: Study update


COMPASS Pathways Slides: Study update

Feb 17, 2026, 8:00 AM EST - 4 months ago

COMPASS Pathways Slides: Study update


COMPASS Pathways Transcript: KOL Event

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Transcript: KOL Event


COMPASS Pathways Press release: KOL Event

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Press release: KOL Event


COMPASS Pathways Slides: KOL Event

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Slides: KOL Event


COMPASS Pathways Slides: Investor Presentation

Jan 7, 2026, 7:00 AM EST - 6 months ago

COMPASS Pathways Slides: Investor Presentation


COMPASS Pathways Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:40 AM EST - 8 months ago

COMPASS Pathways Transcript: Stifel 2025 Healthcare Conference


COMPASS Pathways Slides: Investor Presentation

Nov 4, 2025, 9:30 AM EST - 8 months ago

COMPASS Pathways Slides: Investor Presentation


COMPASS Pathways Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

COMPASS Pathways Earnings Call Transcript: Q3 2025


COMPASS Pathways Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

COMPASS Pathways Quarterly report: Q3 2025


COMPASS Pathways Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

COMPASS Pathways Earnings release: Q3 2025


COMPASS Pathways Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

COMPASS Pathways Earnings Call Transcript: Q2 2025


COMPASS Pathways Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

COMPASS Pathways Earnings release: Q2 2025


COMPASS Pathways Quarterly report: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

COMPASS Pathways Quarterly report: Q2 2025


Compass Pathways Appoints Justin Gover to Board of Directors

Jul 29, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways Appoints Justin Gover to Board of Directors


Compass Pathways' depression drug succeeds late-stage trial

Jun 23, 2025, 6:48 AM EDT - 1 year ago

Compass Pathways' depression drug succeeds late-stage trial


wizkid1774
wizkid1774 Jul. 4 at 11:58 PM
$CMPS I think in the next couple of weeks we are going to see some good things.
0 · Reply
Millionaire11
Millionaire11 Jul. 3 at 5:49 PM
$CMPS remember 2020 when this hyped all the way up to $60. Everything they were hyped about is happening NOW. Buckle up!
2 · Reply
QuietlyAccumulating
QuietlyAccumulating Jul. 3 at 12:02 AM
$CMPS https://thesporereport.com/psilocybin-could-help-repair-the-physical-nerve-damage-caused-by-chemotherapy/
1 · Reply
Waldo_5150
Waldo_5150 Jul. 2 at 11:29 PM
$CMPS ... "When a company files a New Drug Application (NDA) for a second indication, they don't start from scratch. COMPASS can directly copy and paste massive sections of their TRD filing into their PTSD filing" .........
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 10:12 PM
One of the strongest sectors outside of AI right now is Biotech. Neurology $DFTX Definium Therapeutics $CMPS COMPASS Pathways $DNLI Denali Therapeutics $XENE Xenon Pharmaceuticals $NBIX Neurocrine Biosciences The 70% correction trap is driving smart money into neuro-therapeutic CNS alpha pipelines. Elite institutions deploy tactical limit entries atop long-term FIB floors, lock-floating neurological monopolies. Disrupter DFTX accelerates right-side PEG defense, surging on its upsized $805M public offering and pivotal Phase 3 depression data catalysts. It pairs with psychedelic pioneer CMPS at key FIB accumulation zones, while blood-brain-barrier innovator DNLI scales following fresh Russell growth index flows. Flanking them are commercial powerhouse BIIB and pipeline leader XENE hardening their valuation ceilings. Technical compression means nothing without clinical milestones. Facing this neuro-rotation, are you buying the FIB support floors on DFTX and CMPS or resting in defensive cash?
1 · Reply
Millionaire11
Millionaire11 Jul. 2 at 10:07 PM
$CMPS 10 billion dollar market cap in the making. Millionaires in the making.
1 · Reply
twiggs462
twiggs462 Jul. 2 at 9:03 PM
$DFTX $CMPS from a couple days ago, but nice to see the coverage https://youtu.be/srT4HUojtFU?t=277&is=5X6xYSBewrec4r2s
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jul. 2 at 8:24 PM
$CMPS and $ATAI hit simultaneously in 2 minute intervals from 1:43 to 1:47 with violent, price-insensitive market order sweeps. They represented the cleanest profiles for a fund looking to deploy massive blocks into late-stage TRD pipelines. Interesting tells lay in the divergences. DFTX lagged the initial move significantly. Why? They recently closed an upsized $805M offering. That massive capital injection means float mechanics are structurally clogged with overhead supply. The market had to chew through those shares before moving up in sympathy. Meanwhile, HELP completely decoupled from the sector and flatlined. This is the risk-management filter in action. With an escalating cash burn and recent $50M underwritten dilutive offering, buy programs bypassed them. Smart money doesn’t blindly chase. They swept liquid leaders ($CMPS / $ATAI), slowly absorbed the high-supply player (DFTX)and deliberately avoided (HELP). This was simply institutional capital seeking de-risked milestones.
3 · Reply
martybecker123
martybecker123 Jul. 2 at 8:07 PM
$CMPS I guess it bounced off the bottom of the channel (or close enough). Back up we go, until 15-something at least. But hopefully we'll break out at some point.
0 · Reply
1TimeDealer
1TimeDealer Jul. 2 at 8:03 PM
$CMPS great way to head into the 250th Celebration! Whats everyones best guesses on what the stock price will be before new data??
0 · Reply
Waldo_5150
Waldo_5150 Jul. 2 at 7:44 PM
$CMPS ... Nice way to go into a long Holiday weekend !!! ...
0 · Reply
Millionaire11
Millionaire11 Jul. 2 at 7:12 PM
$CMPS we might get results quicker than we think. Institutions piling in before July 4th. Maybe we get them next week. Pure speculation
2 · Reply
psyxopathis
psyxopathis Jul. 2 at 6:55 PM
$CMPS https://www.congress.gov/bill/119th-congress/house-bill/9559?__cf_chl_f_tk=3DUeSmbxfeBkLkP3F.MTol8W9910hrZxSH5zUhiwIzI-1783018099-1.0.1.1-oFvpasLo8XHXziqWYg_gETVqK7Vklk5gfTR28tmmyN4
0 · Reply
Waldo_5150
Waldo_5150 Jul. 2 at 6:20 PM
$CMPS ... COMP360 would've helped ..... NEWS: July 2nd : New Jersey Republican Rep. Tom Kean Jr. disclosed Tuesday that he was being treated for depression during his unexplained four-month absence from the House, suggesting in a brief floor speech that he remained silent about his condition until now because he is a “private person by nature.” Depression, Kean said, “is physical, it is emotional, and until you experience it yourself, it is difficult to fully understand how powerful this illness can be.” ..............
0 · Reply
ClownThePoet
ClownThePoet Jul. 2 at 6:07 PM
$CMPS USA USA USA
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jul. 2 at 6:01 PM
$CMPS What just happened is visible in the 1 minute chart. 200,000 shares were bought at once and then 2 minutes later 220,000 shares were bought again at once. Many institutions dont play games buying small share quantities. If the price reaches a level that makes sense then the algo will push the order. Somebody picked up $5,500,000 worth of CMPS in 2 minutes. They will sit there and let retail unload in panic so they can grow their position at a discount. You just saw why the rich get richer and the poor stay poor.
3 · Reply
jmash
jmash Jul. 2 at 5:54 PM
$ATAI $CMPS $DFTX does explain the pop?
1 · Reply
Aightmatey
Aightmatey Jul. 2 at 5:52 PM
$CMPS what just happened?
1 · Reply
QuantGhost
QuantGhost Jul. 2 at 5:52 PM
$CMPS why the spike?
0 · Reply
thevert123
thevert123 Jul. 2 at 5:29 PM
$CMPS to ease minds and help people make money. This is seriously a gift. I wish i had more dust. I've been adding every day and im getting too low, but cmps is in sync when nasdaq today. You can see the similarities in the chart. Its not always because something is wrong with a particular stock. Sometimes there are a lot of outside factors. We are playing the waiting game. Mostly everyone is loaded and waiting. Algos are set to sell today so it's just one of those days. A lot of people are shaky. Well understood. This data isn't so much about IF it works its about how much better 2 doses is compared to 1 dose. Then after the data is out, it's the road to fda approval. Pretty bullish they hired a bunch of new people. I don't think they'd be stacking up salaries if the data was going to be disappointing.
1 · Reply
Dazza933
Dazza933 Jul. 2 at 5:18 PM
$CMPS I believe in this company and product. It is that simple. I am up over 200% so got a good entry point, and been on my radar for five years. 2026 - 2027, a year full of catalysts. Phase 3 durability data likely this month or first half August. NDA submission by EOY. FDA approval Q1 2027 likely. Financial runway to 2028. Product pipeline that can help millions, with a framework of providers already set for a frictionless go to market strategy. We are not at the Casino. There is no quick Vegas money here. Week to week price movements is irrelevant. Trends are positive. We are in the best situation for company and stock in half a decade. My price target based on my own DD is $58.25, and I am bullish
0 · Reply
Aightmatey
Aightmatey Jul. 2 at 5:17 PM
$CMPS this is just noise; nothing has changed. Bought more today.
0 · Reply